FDA Grants Priority Review to Mirabegron for NDO

  In early January 2021, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that its New Drug Application (NDA) and supplemental NDA for Myrbetriq (mirabegron) received Priority Review status from the…

Continue Reading FDA Grants Priority Review to Mirabegron for NDO